IX Biopharma

IX Biopharma EBIT Margin

The EBIT Margin (Operating Margin) of IX Biopharma (42C.SI) as of Oct 21, 2026 is -138.68 %. In the previous year, EBIT Margin (Operating Margin) was -80.92 % — a change of 71.39% (lower).

EBIT Margin

-138.68 %

YoY

71.39%

Last updated:

EBIT Margin (Operating Margin) of IX Biopharma is 2026 -138.68 % . EBIT Margin (Operating Margin) of IX Biopharma was 2025 -80.92 % . It decreases by 71.39% lower compared to the previous year.

For IX Biopharma, the operating (EBIT) margin of -138.7% is down versus 3.8% a few years ago.

The IX Biopharma EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-1,971.68 SGD
Jan 1, 2020
-1,133.10 SGD
Jan 1, 2021
-654.96 SGD
Jan 1, 2022
3.76 SGD
Jan 1, 2023
-161.41 SGD
Jan 1, 2024
-160.14 SGD
Jan 1, 2025
-80.92 SGD
Jan 1, 2026
-138.68 SGD
The IX Biopharma EBIT Margin history
YEAREBIT MarginYoY
-138.68 %+71.39%
-80.92 %-49.47%
-160.14 %-0.78%
-161.41 %-4,393.25%
3.76 %-100.57%
-654.96 %-42.20%
-1,133.10 %-42.53%
-1,971.68 %-69.05%
-6,371.14 %+3,782.55%
-164.10 %+22.22%
-134.26 %+1.14%
-132.75 %-33.65%
-200.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

IX Biopharma Stock analysis

What does IX Biopharma do? IX Biopharma Ltd is a leading biopharmaceutical company based in Singapore. The company was founded in 2007 by Dr. Jan-Olof Heldin, a globally recognized biotech entrepreneur. The history of IX Biopharma dates back to the late 90s, when Dr. Heldin began working on a new method of drug delivery called "Oral Transmucosal Technology" (OTM). This technology allows for the development of drugs that can quickly and specifically penetrate the body, with a very high bioavailability. Today, IX Biopharma has a strong presence in the market for novel OTM-based drugs. The company operates in three different business areas: human medicine products, animal health, and life sciences. IX Biopharma's human medicine products are specialized in the treatment of pain and inflammation. The company has already launched a product - a fast-acting spray for pain relief. This new technology allows the medication to quickly enter the body and take effect, providing patients with rapid pain relief. IX Biopharma is currently working on additional products based on OTM technology to provide suitable solutions for other medical conditions as well. In the animal health sector, IX Biopharma offers veterinary products tailored to the needs of pets and livestock. The company collaborates closely with veterinarians and livestock experts to develop innovative therapies and treatment methods customized for specific animal needs. In the field of life sciences, IX Biopharma engages in a wide range of activities and services. These include the development of diagnostic products, conducting clinical trials, identifying biomarkers, and developing immunotherapies. Overall, IX Biopharma is an innovative biopharmaceutical company specializing in the development of drugs based on new technologies. The company is constantly striving to find innovative solutions to improve the health of humans and animals. With a dedicated team of scientists and researchers, as well as a strong presence in Asia and Europe, IX Biopharma is a pioneer in the new world of OTM-based drug development. IX Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IX Biopharma stock

EBIT Margin (Operating Margin) of IX Biopharma is -138.68 % in 2026.

EBIT Margin (Operating Margin) of IX Biopharma changed from -80.92 % to -138.68 %, representing a 71.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) IX Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s IX Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — IX Biopharma

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — IX Biopharma